1. Home /
  2. Pharmaceuticals


Fingers Crossed for a Small-Cap Revenge Rally in 2022

The lingering effects of the pandemic have been hard on smaller biotech and healthcare stocks, but the worm could turn next year.

Why Are Insiders Buying These 2 Beaten Down Small-Cap Biopharmas?

Eyenovia and BioDelivery Sciences are their targets.

McCarthy Stalls, Europe's COVID Surge, Mad Love for Ford, Apple's Car Play

Plus, the headline numbers don't come close to telling the story of Thursday's action in the equity markets, which had a case of bad breadth.

Johnson & Johnson Joins the Breakup Club: Here's How to Play It

J&J will be separating into two distinct firms, but not right away.

Moderna's Patent Credit, Palantir and ARK, Musk Sells Tesla as EV Stocks Climb

Plus, the intersection of rising inflation and a slowing velocity of money give us reason for pause.

Traders Should Be Stopped Out of Biohaven Pharmaceutical

For now I would take a wait and see approach.

How to Play AstraZeneca as Earnings Approach

Let's see how the charts are shaping up ahead of the numbers Friday.

I See a Direction for Compass Pathways

It may have a tough pill to swallow right now, but I'm still optimistic about psilocybin in general, and especially Cybin.

GT Biopharma Must Learn How to Play the Game ... and Explain Itself

Let's look at the rookie mistake the biopharma made on Monday, and what makes the company still hold promise for investors -- if it explains its C-suite moves.

Nasdaq Runs Higher, Semis Run Hot, EV Market Heats Up, Peloton Cools Down

Plus, we continue to wait with bated breath to see where Congress goes with President Biden's two big spending initiatives.